2012•International Journal of CardiologyRequires access

OP-232 ROSUVASTATIN VERSUS ATORVASTATIN IN PREVENTING CONTRAST INDUCED NEPHROPATHY AMONG PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION (ROSA-CIN TRIAL)

Ayşem Kaya, Meral Kurt, İbrahi̇m Hali̇l Tanboğa, T. Isik, Mehmet Ekinci, Enbiya Aksakal, Serdar Sevimli

Open publisher page 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Rosuvastatin, Atorvastatin, Contrast-induced nephropathy, Percutaneous coronary intervention, Nephropathy, Internal medicine, Cardiology

Back to paper search Browse research topics Original source

OP-232 ROSUVASTATIN VERSUS ATORVASTATIN IN PREVENTING CONTRAST INDUCED NEPHROPATHY AMONG PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION (ROSA-CIN TRIAL) — Research Paper | ScholarLens